62nd ASH Annual Meeting and Exposition: 703. Adoptive Immunotherapy: Poster I

Oral and Poster Abstracts
Poster

Adult, ALL, AML, Biological, Leukemia, multiple myeloma, Animal models, bioengineering, CLL, Diseases, iPSCs, Lymphoma (any), CAR-Ts, Combinations, Elderly, Hodgkin Lymphoma, Mantle Cell Lymphoma, Therapies, Adverse Events, Non-Hodgkin Lymphoma, Pediatric, B-Cell Lymphoma, Biological Processes, DLBCL, cell expansion, gene therapy, immune cells, Technology and Procedures, Young Adult, Cell Lineage, immunotherapy, Plasma Cell Disorders, Xenograft models, gene editing, Lymphoid Malignancies, Study Population, Clinically relevant, Myeloid Malignancies, NK cells, imaging, flow cytometry, TKI, stem cells, metabolomics, microenvironment, RNA sequencing

1428

Clinical Development of a Non-Gene-Edited Allogeneic Bcma-Targeting CAR T-Cell Product in Relapsed or Refractory Multiple Myeloma

A. Samer Al-Homsi, MD¹, Sebastien Anguille, MD²^*, Jason Brayer, PhD, MD³, Dries Deeren, MD, PhD⁴, Nathalie Meuleman, PhD, MD⁵^*, Gareth Morgan, MD, PhD, FRCP¹^*, Taiga Nishihori, MD⁶, Panagiota A. Sotiropoulou, PhD⁷^*, Laure Twyffels, PhD⁷^*, Jennifer Bolsee, PhD⁷^*, Nathalie Braun⁷^*, Caroline Lonez, PhD⁸^*, David E Gilham, PhD⁷^*, Anne Flament, MD⁷^* and Frédéric F. Lehmann, MD⁷^*

¹NYU Langone Health, New York University School of Medicine, New York, NY
²Antwerp University Hospital, Antwerp, Belgium
³H. Lee Moffitt Cancer Center, Tampa, FL
⁴Algemeen Ziekenhuis (AZ) Delta, Roeselare, Belgium
⁵Department of Hematology, Institut Jules Bordet (ULB), Brussels, Belgium
⁶Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL
⁷Celyad Oncology, Mont-Saint-Guibert, Belgium
⁸Celyad Oncology, Mont-saint-Guibert, Belgium

1429

Targeted Integration of a CAR at a Novel Genomic Safe Harbor Directs Potent Therapeutic Outcomes

Ashlesha Odak, MS^1,2^*, Han Yuan, PhD^3,4^*, Judith Feucht, MD⁵^*, Jorge Mansilla - Soto, PhD²^*, Justin Eyquem, PhD^2,6, Christina Leslie, PhD³^* and Michel Sadelain, MD, PhD⁷

¹Weill Cornell Graduate School, Weill Cornell Medicine, New York, NY
²Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY
³Computational Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY
⁴Calico Life Sciences, San Francisco, CA
⁵Memorial Sloan Kettering Cancer Center, New York, NY, Germany
⁶University of California San Francisco, San Francisco, CA
⁷Center for Cell Engineering and Immunology Program, Memorial Sloan Kettering Cancer Center, New York City, NY

1430

Axl-RTK Inhibition Modulates Monocyte Immune Response to Enhance the Anti-Tumor Effects of CD19 Redirected Chimeric Antigen Receptor T Cells in Preclinical Models

Reona Sakemura, MD, PhD^1,2, Michelle J. Cox^1,2,3, Elizabeth L. Siegler, PhD^1,2^*, Erin E. Tapper^1,2^*, Wendy K. Nevala⁴^*, Mehrdad Hefazi, MD^1,2, Claudia Manriquez Roman^1,2,5,6^*, Kendall J. Schick^1,2,6,7^*, Ismail Can^1,2,6^*, Evandro D. Bezerra, MD^1,2, Lionel Kankeu Fonkoua, MD^1,2, Paulina Horvei, MD^1,8, Michael W. Ruff, MD^1,9^*, Lars Mouritsen¹⁰^*, Jason M. Foulks, PhD¹⁰^*, Steven L. Warner, PhD¹⁰, Wei Ding, MD, PhD², Susan L. Slager, PhD², Sameer A. Parikh, MD², Neil E. Kay, MD² and Saad S. Kenderian, MD^1,2,4,5

¹T Cell Engineering, Mayo Clinic, Rochester, MN
²Division of Hematology, Mayo Clinic, Rochester, MN
³Bioinformatics and Computation Biology, University of Minnesota Graduate School, Rochester, MN
⁴Department of Immunology, Mayo Clinic, Rochester, MN
⁵Department of Molecular Medicine, Mayo Clinic, Rochester, MN
⁶Mayo Clinic Graduate School of Biomedical Sciences, Rochester, MN
⁷Department of Molecular Pharmacology & Experimental Therapeutics, Mayo Clinic, Rochester, MN
⁸Department of Pediatrics, University of California San Francisco, San Francisco, CA
⁹Department of Neurology, Mayo Clinic, Rochester, MN
¹⁰Tolero Pharmaceuticals, Inc., Lehi, UT

1431

Metabolically Flexible CAR T Cells (mfCAR-T), with Constitutive Expression of PGC-1α Resistant to Post Translational Modifications, Exhibit Superior Survival and Function in Vitro

Reginald M Atkins, PhD¹^*, Meghan A Menges¹^*, Alexis Bauer, BS²^*, Joel G. Turner, PhD² and Frederick L. Locke, MD³

¹Clinical Science Division, Moffitt Cancer Center, Tampa, FL
²Chemical Biology and Molecular Medicine Program, Moffitt Cancer Center, Tampa, FL
³Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL

1432

Vesicular Stomatitis Virus (VSV) Engineered to Express CD19 Stimulates Anti-CD19 Chimeric Antigen Receptor Modified T Cells and Promotes Their Anti-Tumor Effects

Reona Sakemura, MD, PhD^1,2, Elizabeth C. Eckert, PhD^3,4^*, Sydney B. Crotts^5,6^*, Linh Pham³^*, Elizabeth L. Siegler, PhD^1,2^*, Michelle J. Cox^1,2,7, Erin E. Tapper^1,2^*, Mehrdad Hefazi, MD^1,2, Claudia Manriquez Roman^1,2,3,6^*, Kendall J. Schick^1,2,6,8^*, Ismail Can^1,2,6^*, Evandro D. Bezerra, MD^1,2, Lionel Kankeu Fonkoua, MD^1,2, Paulina Horvei, MD^1,9, Michael W. Ruff, MD^1,10^*, Susan L. Slager, PhD², Sameer A. Parikh, MD², Neil E. Kay, MD², Kah-Whye Peng, PhD³^*, Stephen J. Russell, MD, PhD^2,3 and Saad S. Kenderian, MD^1,2,3,5

¹T Cell Engineering, Mayo Clinic, Rochester, MN
²Division of Hematology, Mayo Clinic, Rochester, MN
³Department of Molecular Medicine, Mayo Clinic, Rochester, MN
⁴Clinical and Translational Science Track, Mayo Clinic Graduate School of Biomedical Sciences, Rochester, MN
⁵Department of Immunology, Mayo Clinic, Rochester, MN
⁶Mayo Clinic Graduate School of Biomedical Sciences, Rochester, MN
⁷Bioinformatics and Computation Biology, University of Minnesota Graduate School, Rochester, MN
⁸Department of Molecular Pharmacology & Experimental Therapeutics, Mayo Clinic, Rochester, MN
⁹Department of Pediatrics, University of California San Francisco, San Francisco, CA
¹⁰Department of Neurology, Mayo Clinic, Rochester, MN

1433

Tonic Signaling Leads to Off-Target Activation of T Cells Engineered with Chimeric Antigen Receptors That Is Not Seen in T Cells Engineered with T Cell Antigen Coupler (TAC) Receptors

Duane Moogk^*, Arya Afsahi, MSc^*, Vivian Lau, MSc^*, Anna Dvorkin-Gheva, PhD^* and Jonathan Bramson, PhD^*

Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada

1434

Multiplexed Engineered, Off-the-Shelf T Cells Carrying Three Tumor-Associated Antigen-Targeting Modalities: CAR + Pan-Tumor Targeting TCR + CD16 Fc Receptor

Cokey Nguyen, PhD^1,2^*, Eigen Peralta, PhD²^*, Chia-Wei Chang³^*, Wen-I Yeh, PhD¹^*, Yijia Pan, PhD¹^*, Dan Lu, PhD²^*, May Sumi¹^*, Mochtar Pribadi, PhD³^*, Bi-Huei Yang, PhD¹^*, Eric Sung²^*, Alec Witty, PhD¹^* and Tom Lee, PhD²^*

¹Fate Therapeutics Inc., San Diego, CA
²Fate Therapeutics, Inc., San Diego, CA
³Fate Therapeutics, San Diego, CA

1435

NTLA5001, a T Cell Product Candidate with CRISPR-Based Targeted Insertion of a High-Avidity, Natural, WT1-Specific TCR, Shows Efficacy in In Vivo Models of AML and ALL

Eliana Ruggiero, PhD¹^*, Dai Liu, PhD²^*, Aaron Prodeus, PhD²^*, Amy M Becker, PhD²^*, Maxwell Foisey, BS²^*, Ishina Balwani, MS²^*, Ivy Dutta, MS²^*, Qingzhan Zhang, PhD²^*, Simo M Arredouani, PhD²^*, Mark McKee, MD³^*, Fabio Ciceri, MD^4,5^*, Laura Sepp-Lorenzino, PhD⁶^*, Chiara Bonini, MD^1,7 and Birgit C Schultes, PhD²

¹Experimental Hematology Unit, Division of Immunology, Transplantation and Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy
²Cell Therapy, Intellia Therapeutics, Cambridge, MA
³Clinical Development, Intellia Therapeutics, Cambridge, MA
⁴San Raffaele Scientific Institute, Hematology and Bone Marrow Transplantation Unit, Milano, Italy
⁵Pathology Unit, San Raffaele Scientific Institute, Milan, Italy
⁶Research, Intellia Therapeutics, Cambridge, MA
⁷Vita-Salute San Raffaele University, Milan, Italy

1436

Preclinical Development of Edit-201, a Multigene Edited Healthy Donor NK Cell with Enhanced Anti-Tumor Function and Superior Serial Killing Activity in an Immunosuppressive Environment

Christopher M Borges, PhD, BS, Kevin Wasko^*, Jared M Nasser^*, Kelly Donahue^*, Amanda Pfautz^*, Lincy P Antony^*, Glenn Leary^*, Steven Sexton^*, Richard A. Morgan, PhD and Karrie K Wong, PhD

Editas Medicine, Cambridge, MA

1437

CD38-Directed CAR-T Cell Therapy: A Novel Immunotherapy Strategy for Relapsed Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation

Xiaowen Tang, MD, PhD^1,2^*, Depei Wu, MD, PhD^1,2, Qingya Cui^1,2^*, Chongsheng Qian^2,3^*, Nan Xu^4,5^*, Liqing Kang^4,5^*, Haiping Dai^1,2^*, Baoquan Song^1,2^*, Wei Cui^1,2^*, Jia Yin^2,3^*, Zheng Li^2,3^* and Lei Yu, MD, PhD^4,5^*

¹National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China
²Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China
³National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China
⁴School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, China
⁵Shanghai Unicar-Therapy Bio-Medicine Technology Co., Ltd, Shanghai, China

1438

CAR-T Cells with High CAR Expression Intensity Have Improved In Vitro and In Vivo Anti-Lymphoma Effect without Functional Exhaustion

ANA Carolina Carolina CABALLERO González^1,2^*, Laura Escribà-García, PhD³^*, Paula Pujol-Fernández³^*, Eva Escudero-López³^*, Rosanna Montserrat³^*, Cristina Ujaldón-Miró³^*, Jorge Sierra, MD³, Carmen Alvarez-Fernández, PhD³^* and Javier Briones, MD, PhD³^*

¹Josep Carreras Leukaemia Research Institute, Barcelona, Spain
²Hematology Department, Hospital de la Santa Creu i Sant Pau, BARCELONA, Spain
³Hematology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

1439

OrthoCARs: Engineered human IL-2/IL-2Rb orthogonal pairs selectively enhance CAR T cell antitumorefficacy

Paul-Joseph Aspuria¹^*, Michael A Bauer, PhD², Sandro vivona¹^*, Rene de Waal Malefyt¹^*, Rob Kastelein¹^*, Martin Oft³^*, Jan Emmerich¹^*, Deepti Rokkam¹^*, Steven E Kauder, PhD⁴^*, Scott McCauley⁵^*, Romina Riener¹^* and Rakesh Verma, PhD⁶

¹Synthekine, Inc., Menlo Park, CA
²Department of Biomedical Informatics, University of Arkansas For Medical Sciences, Little Rock, AR
³ARMO Biosciences, Redwood City, CA
⁴Alexo Therapeutics, South San Francisco, CA
⁵Lilly, Redwood City, CA
⁶MMCRI, Maine Medical Center, New Haven, CT

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

703.P1.36 703. Adoptive Immunotherapy: Poster I